Friedman, Deborah
Dozor, Allen J.
Milner, Jordan
D’Souza, Marise
Talano, Julie-An
Moore, Theodore B.
Shenoy, Shalini
Shi, Qiuhu
Walters, Mark C.
Vichinsky, Elliott
Parsons, Susan K.
Braniecki, Suzanne
Moorthy, Chitti R.
Ayello, Janet
Flower, Allyson
Morris, Erin
Mahanti, Harshini
Fabricatore, Sandra
Klejmont, Liana
van de Ven, Carmella
Baxter-Lowe, Lee Ann
Cairo, Mitchell S. http://orcid.org/0000-0002-2075-434X
Funding for this research was provided by:
U.S. Department of Health & Human Services | U.S. Food and Drug Administration (R01FD004090)
Pediatric Cancer Research Foundation
Article History
Received: 9 December 2020
Revised: 23 March 2021
Accepted: 8 April 2021
First Online: 6 May 2021
Compliance with ethical standards
:
: MSC has received funding from the FDA (R01FD004090), the Pediatric Cancer Research Foundation (PCRF), Otsuka and Miltenyi. Although not related to this study, MCW is a consultant for Bluebird Bio, Inc., Bioverativ, Sangamo, Veevo, Editas Medicine and is medical director for AllCells, Inc. Biosciences. SKP is a consultant to Seattle Genetics, also unrelated to this study. EV is a consultant for ApoPharma, on the advisory committee for Global Blood Therapeutics and receives royalties from UptoDate. All other authors declare no conflicts of interest.
: The protocol was approved at each institutional review board, informed consent was obtained and assent was obtained if clinically applicable and the study was registered at ClinicalTrials.gov NCT01461837. This research has been presented in part at the American Society of Hematology (ASH), December 2017, San Diego, CA.